CD4 and neoplasm: In patients who responded to pembrolizumab, the effector‐type cellular neighbourhoods (CNs), including a tumor/DC CN and a tumor/CD4+ T‐cell CN, were significantly increased, while in non‐responder an immunosuppressive‐type CN enriched in regulatory T cells was significantly increased following treatment.